RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:The TRIM3/TLR3 axis overrides IFN-β feedback inhibition to suppress NSCLC progression.
The TRIM3/TLR3 axis overrides IFN-β feedback inhibition to suppress NSCLC progression.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
干扰素-β(IFN-β)具有强效抗肿瘤活性,但其临床治疗潜力受到抑制IFN-β产生的内在负反馈环路的削弱。然而,非小细胞肺癌(NSCLC)中调控IFN-β稳态的反馈机制仍不清楚。
我们发现,三重基序包含蛋白3(TRIM3)促进IFNB1的转录和mRNA表达。相反,过量的IFN-β抑制TRIM3的表达,形成二者之间的相互反馈环路。质谱分析显示,toll样受体3(TLR3)——触发IFN-β产生的关键感受器——是TRIM3的相互作用伙伴。在阐明TRIM3与TLR3之间的相互作用模式后,我们发现TRIM3/TLR3轴的激活诱导IFN-β分泌并克服了反馈抑制。持续的IFN-β分泌随后抑制NSCLC细胞增殖,并通过增加CD4+ T细胞、M1巨噬细胞和NK细胞的浸润水平重塑肿瘤微环境。
我们的发现揭示了IFN-β信号调控中的相互负反馈环路,突出了TRIM3/TLR3轴在抑制NSCLC进展中的作用,并为抑制NSCLC肿瘤生长和增强免疫治疗疗效提供了一种有前景的策略。
Interferon-beta (IFN-β) has potent antitumor activity, but its clinical therapeutic potential is undermined by intrinsic negative feedback loops that suppress IFN-β production.
However, the feedback mechanisms regulating IFN-β homeostasis in non-small cell lung cancer (NSCLC) remain unclear.
We found that tripartite motif containing 3 (TRIM3) promotes the transcription and mRNA expression of IFNB1. Conversely, excessive IFN-β inhibits expression of TRIM3, creating their reciprocal feedback loop. Mass spectrometry revealed that toll-like receptor 3 (TLR3), a key sensor that triggers IFN-β production, is the interacting partner of TRIM3.
Following the elucidation of the interactive mode between TRIM3 and TLR3, we found that activation of the TRIM3/TLR3 axis induced IFN-β secretion and overrode the feedback inhibition. Sustained IFN-β secretion subsequently inhibits NSCLC cell proliferation and reprograms the tumor microenvironment by increasing the infiltration levels of CD4 + T cells, M1 macrophages and NK cells.
Our findings revealed a reciprocal negative feedback loop in the regulation of IFN-β signaling, highlighting the role of the TRIM3/TLR3 axis in the suppression of NSCLC progression and offering a promising strategy to suppress tumor growth and enhance immunotherapy efficacy in NSCLC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。